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Levetiracetam (LEV) is a new antiepileptic drug with a promising preclinical profile involving both anticonvulsant and antiepilep-
togenic effects in kindling models. The latter stimulated the present study to compare its neuroprotective properties with the
potent and selective, non-competitive NMDA antagonist, MK-801, in the rat middle cerebral artery occlusion model. Twenty-
four hours after a transient occlusion of 90 minutes the animals were sacrificed and infarct volume and lesion distribution were
determined from stained coronal sections. LEV was administered by intraperitoneal (i.p.) bolus injections of 5.5, 11, 22 and
44 mg kg−1, 30 minutes before occlusion followed by a continuous 24 hour i.p. infusion of 1.25, 2.6, 5.1 and 10.2 mg kg−1 per
hour, respectively. LEV administration did not alter body temperature but reduced the infarct volume by 33% (P< 0.05) at the
highest dose tested. An i.p. bolus injection of 0.04, 0.12 and 0.4 mg kg−1 of MK-801 followed by continuous i.p. infusion of
0.036, 0.108 and 0.36 mg kg−1 per hour, reduced the infarct volume by 49, 51 and 74% (P< 0.05), respectively. However, only
the highest dose of MK-801 induced a significant reduction in the infarct volume (P< 0.05) and this was associated with hy-
pothermia. These results suggest that LEV possesses neuroprotective properties which may be relevant for its antiepileptogenic
action.
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INTRODUCTION
Levetiracetam (LEV) is a new antiepileptic drug with
a promising preclinical profile1. Previous studies sug-
gest that LEV provides seizure protection in various
animal seizure models and displays a favourable safety
margin1–3. Furthermore, it has recently been demon-
strated that LEV produces antiepileptogenic effects
in an animal kindling model during kindling devel-
opment at doses which are devoid of sedative and
ataxiogenic adverse effects4. This contrasts with es-
tablished antiepileptic drugs (AEDs) of which only
valproate and, to a lesser extent, phenobarbital reveal
antiepileptogenic effects, but only at high doses asso-
ciated with severe adverse effects5. These results sug-
gest that LEV might not only be a novel drug for the
symptomatic treatment of epilepsy, but also for the
pharmacological prevention of this disease.
The most common neuropathological finding in
temporal lobe epilepsy (TLE) is mesial temporal scle-
rosis, which primarily affects the hippocampus and
other limbic structures6. Observations in animal mod-
els of epilepsy, as well as in human epilepsy, sug-
gest that TLE involves a substantial neuronal loss
and an associated axonal reorganization (mossy fi-
bre sprouting) which may induce the epileptogenic
condition7. This suggests that drugs preventing neu-
ronal death may counteract the epileptogenic process,
although the precise mechanisms by which the hip-
pocampus and other limbic structures generate epilep-
tic discharges in TLE remains to be elucidated.
Studies in animals have shown a potent action of
NMDA antagonists against both neuronal death asso-
ciated with cerebral ischemia8 as well as antiepilep-
togenic effects against kindling development9. This
supports a correlation between neuronal death and
epileptogenesis7. Thus, the antiepileptogenic proper-
ties of LEV in the kindling model prompted us to study
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its potential neuroprotective properties against exper-
imental ischemia in rodents. For comparison, we also
evaluated the effect of the non-competitive NMDA an-
tagonist, MK-801.
MATERIALS AND METHODS
Animals
Adult male rats (Wistar) weighing 300–350 g were
used. The animals were fed ad libitum and were main-
tained on a 12 hour light/dark cycle. All animals were
weighed before surgery and 24 hours later, before be-
ing killed.
Middle cerebral artery occlusion
Transient focal ischemia was induced by the intralu-
minal suture method10, modified from that originally
described by Koizumi11.
Anaesthesia was induced with a gaseous mixture of
2% isoflurane in N2O+ O2 (70/30 V/V) for ≈5 min-
utes and maintained with a 0.5% mixture delivered
through a face mask (unassisted respiration). Atropine,
0.4 mg kg−1, was injected intraperitoneally (i.p.) to
prevent oversecretion of the respiratory tract. During
surgery, the animals were kept on a heating pad (at
33–34 ◦C) and covered with a small blanket in order
to maintain body (rectal) temperature between 37 and
38 ◦C. The rectal temperature was continuously moni-
tored with a rectal probe inserted to a 4 cm depth from
the anal ring.
A nylon monofilament (number 0.25 from Platil,
Western Germany) was used for the intraluminal oc-
cluder. One extremity was rounded and polished with
metalographic carborandum-coated paper (grains of
13 µm). The filaments were heated to 50 ◦C in a water
bath, immediately prior to use, in order to increase the
flexibility and to avoid perforations during introduc-
tion. The diameter of the filaments was measured with
electronic callipers and those filaments exceeding the
range of 270–290µm were rejected. The carotid bifur-
cation was exposed through a ventral midline incision
of the neck and the common and external carotid ar-
teries were ligated with a 3-0 silk suture. The ptery-
gopalatine artery was occluded with a u-shaped sil-
ver microclip (1 mm wide) lighty pressed around the
artery and a 3-0 silk suture placed around the in-
ternal carotid, 1 mm distal from the bifurcation, but
kept loose until the occluder was fully introduced. The
intraluminal occluder was introduced in the internal
carotid through an arteriectomy near the bifurcation
of the carotid. The length of filament introduced in
the carotid and Willis polygon was between 18 and
18.5 mm. The suture around the internal carotid and
the filament was tightened when the filament was in
the correct position.
An osmotic mini-pump was implanted laterally un-
der the abdominal skin and connected to a catheter
(PE50 polyethylene) opening in the peritoneal cav-
ity in order to infuse treatments over 24 hours. After
completion of the surgery, the anaesthesia was termi-
nated, and the animals were allowed to recover in indi-
vidually thermoregulated cages. If necessary, the tem-
perature of this cage was lowered by up to 6–10 ◦C
in order to maintain the body temperature of animals
between 36 and 38 ◦C and to avoid hyperthermia in-
duced by MCA obstruction. To allow reperfusion in
the MCA territory, the filament was gently retracted
(≈10 mm length) 90 minutes after its insertion, under
a short 2% isoflurane anaesthesia. The animals were
maintained for 1 hour in the thermoregulated cages be-
fore being returned to their home cage. Rectal temper-
ature of the rats subjected to occlusion was measured
at the beginning and at the end of the surgery, 60 min-
utes after occlusion, at the end of the occlusion and
24 hours after surgery (immediately before sacrifice).
Twenty-four hours later, the animals were deeply
anaesthetized with isofurane 2% and decapitated.
Blood samples were taken by puncture of the ab-
dominal vena cava in order to measure plasma lev-
els of LEV. The brains were quickly removed and
rapidly cooled in melting ice for 5 minutes. The brains
were immediately sliced at 4 ◦C with a vibratome into
2 mm coronal sections. Coronal slices were incubated
for 10 minutes at 36–36.5 ◦C in a solution of 1%
triphenyltetrazolium chloride (TTC, Sigma Chemical
Co.), buffered at pH 7.1 with Na2HPO4. Staining was
stopped by plunging the slices into melting ice. The
first slice was at a distance of 3 mm from the frontal
pole. The slices were photographed with a 3CCD cam-
era and digitized. The green component of the colour
(rgb) picture was used to measure the total area and
the unstained area of the slice. The slice was divided
into a right and a left side.
The infarct area was calculated as the difference be-
tween the right unstained area minus the left unstained
area. The total infarct volume was calculated as the
sum of the infarct areas from the frontal pole through
all the five slices, assuming a thickness of 2 mm. The
amount of ischemic damage was expressed in cubic
millimetres.
Frequency maps of lesions were computer-
generated by adding, on a pixel basis, the pictures of
coronal slices cut at the same level. Prior to addition,
the digital pictures were split into their red, green and
blue components. Only the green picture was used.
A cluster analysis was performed to split the popula-
tion of pixels into two sub-populations on the basis of
their green intensity. A binary picture was generated
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at the end of this operation. The pictures were then
centred and rotated in order to match each other. The
binary pictures were added to each other and divided
by the total number of pictures in each group in or-
der to obtain a value for each individual pixel, which
was representative of the number of animals lesioned
at each location. The frequency was colour coded to
increase the legibility of the maps.
Drugs
LEV and (+)-MK-801 (RBI) were dissolved in saline.
Control groups received the vehicle only. MK-801 was
injected i.p., 30 minutes before occlusion, at doses of
0.04, 0.12 or 0.40 mg kg−1 followed by continuous
infusion (24 hours) of 0.036, 0.108, 0.360 mg kg−1
per hour, respectively12. LEV was administered i.p.,
30 minutes before occlusion, at doses of 5.5, 11,
22 and 44 mg kg−1 followed by continuous infusion
(24 hours) of 1.25, 2.6, 5.1 and 10.2 mg kg−1 per hour,
respectively. All the osmotic mini-pumps were primed
by a 3-hour immersion in saline at 37 ◦C in order to
flow immediately when implanted.
Data analysis and statistics
Body temperature and plasma levels of LEV are ex-
pressed as means ± SD and infarct volumes as me-
dians with first and third quartiles. Infarct volumes
were compared with a Kruskal–Wallis test followed by
a non-parametric test corrected for multiple compar-
isons vs. the control group13. The relationship between
administered doses and infarct volume was evaluated
by a linear trend test on ranks14. Body temperatures
were compared using a one-way analysis of variance
followed by a Dunnett’s test. Animals displaying cere-
bral hematoma at necropsy were discarded from the
statistical analysis. The hematoma were most due to a
likely haemorrhage resulting from the introduction of
the occluder. These hematoma were unrelated to the
drug treatment.
Ethical approval
The protocol of middle cerebral artery occlusion was
approved by the local Ethics Committee for laboratory
animals according to Belgian law.
RESULTS
Plasma levels of levetiracetam
The lowest dose of LEV (i.p. bolus 5.5 mg kg−1 + i.p.
infusion 1.25 mg kg−1 per hour) resulted in plasma
levels of 6.5 ± 0.5 µg ml−1 (n= 9) 24 hours after
onset of the infusion. At the same time point, the
doses of 11, 22 and 44 mg kg−1 followed by infu-
sions of 2.6, 5.1, and 10.2 mg kg−1 per hour resulted
in plasma levels of 12.8 ± 1.5 (n= 7), 28.1 ± 7.6
(n= 8) and 58 ± 15 µg ml−1 (n= 8). This appears
within the range of the plasma concentrations obtained
in epilepsy patients. Thus, a metaanalysis on data ob-
tained in the four phase III studies performed so far
with adjunctive therapy of LEV in adults with refrac-
tory partial epilepsy revealed trough plasma levels of
between 6 and 17 µg ml−1 and C1 hour (close to Cmax)
values between 15 and 43 µg ml−1 (unpublished re-
sults of UCB Pharma).
Body temperature
Occlusion of MCA increased body temperature by
0.5–1.5 ◦C during the occlusion and the following
hours, but 24 hours after occlusion the temperature had
returned to baseline (Table 1). Treatment with LEV did
not alter body temperature, whereas the highest dose
of MK-801 (0.4 mg kg−1) significantly reduced the
temperature increase (Table 1).
Infarct volume
Transient MCA occlusion in the vehicle-treated rats
of the LEV and MK-801 control groups resulted in
infarct lesions of 209 mm3 (179–231) and 211 mm3
(116–252), respectively (Figs 1(a) and 1(b)).
LEV administration reduced the infarct volume
(Fig. 1(a)). With a dose of 11 mg kg−1, the median
infarct volume was 149 mm3 (106–203) (P< 0.05),
at a dose of 22 mg kg−1 the volume was 155 mm3
(144–197), and at the highest tested dose, 44 mg kg−1,
the volume was 140 mm3 (108–191) (P< 0.05). The
latter reflects a reduction of 33%. In contrast, no ma-
jor effects were observed with the lowest dose of
5.5 mg kg−1. The linear trend test indicated that the
dose range used induced a progressive reduction in the
infarct volume (P< 0.05).
MK-801 administration also reduced the infarct vol-
ume (Fig. 1(b)). At a dose of 0.04 mg kg−1, the
median infarct volume was 108 mm3 (92–223), at
0.12 mg kg−1, the volume was 107 mm3 (77–254) and
at the highest tested dose, 0.40 mg kg−1, the volume
was 54 mm3 (10–189) (P< 0.05). This represents re-
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Table 1: Effect of LEV and MK-801 on body temperature during and after an MCA occlusion in rats.
Body temperature (◦C)
Treatments Bolus doses n Before End of 1 h after onset End of Before
mg kg−1 i.p. surgery surgery of occlusion occlusion sacrifice
LEV 0 15 37.6± 0.4 37.8± 0.5 38.1± 0.7 37.9± 0.9 37.6± 0.6
5.5 11 37.6± 0.5 38.0± 0.4 38.7± 0.8 38.4± 0.7 37.7± 0.6
11 15 37.5± 0.4 37.6± 0.5 38.3± 0.5 37.4± 0.8 37.4± 0.7
22 14 37.7± 0.4 37.9± 0.4 38.5± 0.7 37.8± 0.6 37.5± 0.5
44 10 37.6± 0.4 37.7± 0.4 38.4± 0.7 37.8± 0.5 37.4± 0.4
MK-801 0 12 37.1± 0.6 37.2± 0.5 38.1± 0.6 38.2± 0.4 38.1± 0.4
0.04 9 36.9± 0.7 37.4± 0.4 37.9± 0.4 38.3± 0.7 37.9± 0.8
0.12 9 37.1± 0.5 37.5± 0.4 37.9± 1.3 38.6± 0.6 38.0± 0.5
0.4 9 36.7± 0.4 37.3± 0.3 36.7± 1.2∗ 37.3± 1.0∗ 37.6± 0.7
All values are means ± SD. ∗ Statistical significance of P< 0.05.
Fig. 1: Infarct volumes (medians and individual data) in animals pretreated with (a), LEV and (b), MK-801, before a transient MCA
occlusion in the rat. ∗ Statistically significant difference from the control group of P< 0.05.
ductions of 49, 51 and 74%, respectively. However,
despite these important reductions in the infarct vol-
ume it should be noted that only the highest dose of
MK-801 induced a significant effect. This relates to a
response in both the control as well as the MK-801
treated groups which were more heterogenous than in
the experiment with LEV (Fig. 1). Furthermore, the
group sizes were also small for the experiment with
MK-801 compared with that for LEV (Table 1). The
linear trend test indicated that the dose range used in-
duced a progressive reduction in the infarct volume
(P< 0.05).
Frequency maps of lesion distribution
Frequency maps indicate that the infarct occurred in
the caudate putamen and in the dorso-lateral and ven-
tral cortex (Fig. 2). The corpus callosum could not be
differentiated from the infarct region due to its low
content of mitochondria, which abolishes a reaction
with TTC. In preliminary experiments, we observed
that increasing the duration of the occlusion from 30 to
120 minutes induced a progression of the lesion from
the caudate putamen to the cortex (data not shown).
These cortical regions appeared to be rescued from
necrosis due to treatment with LEV (Fig. 2). In gen-
eral, MK-801 exerted its effect in the same cortical
regions, but at the highest dose (which produced hy-
pothermia), a more generalized effect was observed
which included the caudate putamen region (Fig. 2).
DISCUSSION
Experiments with models of focal ischemia in several
species have consistently shown that administration
of NMDA antagonists both before and after ischemia
reduce the infarct size, whereas there are more con-
flicting reports from models of global ischemia15. The
present study confirms that preadministration of MK-
801 can reduce the infarct size induced by a middle
cerebral artery occlusion in rats. Indeed, our findings
of a reduction in infarct volume of between 45 and
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Fig. 2: Frequency maps of cerebral infarction on coronal sections at the level of the caudate putamen 24 hours after a transient
MCA occlusion in the rat. The animals were treated with (a), vehicle (n= 15); (b), LEV 5.5 mg kg−1 (n= 11); (c), LEV 11 mg kg−1
(n= 15); (d), LEV 22 mg kg−1 (n= 14); (e), LEV 44 mg kg−1 (n= 10); (f),vehicle (n= 12); (g), MK-801 0.04 mg kg−1 (n= 10); (h),
MK-801 0.12 mg kg−1 (n= 10); (i), MK-801 0.40 mg kg−1 (n= 10).
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72% corroborate previous reports showing a decrease
varying between 15 and 73%8. This supports the va-
lidity of our experimental conditions.
Body (and cerebral) temperature constitute an im-
portant physiological variable in neuroprotection stud-
ies and there is substantial evidence that hypother-
mia confers neuroprotection16. Indeed, it has been re-
ported that MK-801 failed to protect against global is-
chemia if the animals were prevented from becoming
hypothermic after dosing17. Although this notion can
be questioned for focal ischemia, where NMDA re-
ceptor antagonists have been shown to be very effec-
tive even under conditions of strict temperature regula-
tion18, it is clear that hypothermic effects may enhance
the neuroprotection observed after dosing with MK-
801. This appears to be confirmed by the results of the
present study in which only the highest hypothermic
dose of MK-801 induced a significant reduction in the
infarct volume.
Clinical studies with NMDA antagonists in both
stroke15 and epilepsy patients19 have revealed a high
incidence of adverse effects including confusion, im-
paired concentration, agitation and hallucinations. So
far, this has hampered the clinical utility of this class
of compounds. The antiepileptogenic effects observed
in the rat amygdala-kindling model with LEV dur-
ing kindling acquisition4 were obtained with chronic
administration of doses similar to those used in the
present study. Furthermore, neuroprotective effects in
acute ischemia models have previously been observed
both with the established AEDs valproate and pheno-
barbital20 and the newer AEDs tiagabine21 and lamot-
rigine22, all known to possess antiepileptogenic prop-
erties in kindling models (see below). Together with
previous reports7 this supports the finding that the neu-
roprotective properties of LEV may be relevant to its
antiepileptogenic action.
All established AEDs demonstrate marked anticon-
vulsant effects in kindling models (i.e. inhibition of
seizures evoked in fully kindled animals), but only val-
proate and phenobarbital exert antiepileptogenic prop-
erties in these models (i.e. inhibition of kindling devel-
opment)15, 23. Among the newer AEDs, tiagabine24,
vigabatrin25 and lamotrigine26 also reveal antiepilep-
togenic effects in kindling models. In contrast, NMDA
antagonists lack significant anticonvulsant effects, but
show a potent antiepileptogenic action in kindling
models9, 27. LEV demonstrates a dual action in the
kindling paradigm, incorporating both anticonvulsant
effects in fully kindled animals, and antiepileptogenic
effects during kindling acquisition3, 4. Thus, LEV ap-
pears to possess novel properties which distinguish it
from traditional anticonvulsant agents. The results of
the present study suggest that this may be related to
the neuroprotective effects displayed by LEV.
In summary, the present study demonstrates that
LEV induces significant neuroprotection in a rat
model of focal cerebral ischemia. This effect was cor-
related with plasma levels comparable both to those
inducing antiepileptogenic effects against kindling de-
velopment in rats and to those inducing anticonvulsant
effects in epilepsy patients. In line with previous re-
ports7, these results suggest that the neuroprotective
properties of LEV may be relevant to its antiepilepto-
genic action.
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